Xiaobin Wu Sells 578 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNEGet Rating) COO Xiaobin Wu sold 578 shares of BeiGene stock in a transaction on Friday, June 17th. The stock was sold at an average price of $139.60, for a total value of $80,688.80. Following the sale, the chief operating officer now owns 1,010 shares of the company’s stock, valued at $140,996. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Xiaobin Wu also recently made the following trade(s):

  • On Tuesday, June 21st, Xiaobin Wu sold 1,010 shares of BeiGene stock. The stock was sold at an average price of $144.36, for a total value of $145,803.60.
  • On Monday, June 6th, Xiaobin Wu sold 3,410 shares of BeiGene stock. The stock was sold at an average price of $141.99, for a total value of $484,185.90.
  • On Thursday, May 5th, Xiaobin Wu sold 6,725 shares of BeiGene stock. The stock was sold at an average price of $164.35, for a total value of $1,105,253.75.

BGNE opened at $156.20 on Friday. The business’s 50-day moving average is $146.75 and its two-hundred day moving average is $198.32. BeiGene, Ltd. has a 1 year low of $118.18 and a 1 year high of $426.56. The company has a current ratio of 5.05, a quick ratio of 4.87 and a debt-to-equity ratio of 0.03.

BeiGene (NASDAQ:BGNEGet Rating) last posted its earnings results on Thursday, May 5th. The company reported ($4.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.52) by $0.28. BeiGene had a negative return on equity of 40.10% and a negative net margin of 218.25%. The company had revenue of $306.60 million for the quarter, compared to analyst estimates of $300.41 million. The company’s revenue for the quarter was down 49.4% compared to the same quarter last year. As a group, research analysts anticipate that BeiGene, Ltd. will post -15.13 EPS for the current fiscal year.

Several analysts recently weighed in on the company. Morgan Stanley lifted their price objective on BeiGene from $330.00 to $338.00 and gave the company an “overweight” rating in a report on Tuesday, April 12th. SVB Leerink downgraded BeiGene from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $300.00 to $177.00 in a report on Thursday, March 17th. Finally, StockNews.com downgraded BeiGene from a “hold” rating to a “sell” rating in a report on Thursday, June 16th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BeiGene currently has an average rating of “Moderate Buy” and a consensus target price of $315.33.

Several hedge funds have recently modified their holdings of the company. Bank of America Corp DE grew its stake in shares of BeiGene by 77.1% during the first quarter. Bank of America Corp DE now owns 414,466 shares of the company’s stock worth $78,169,000 after acquiring an additional 180,470 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of BeiGene by 155.4% during the first quarter. The Manufacturers Life Insurance Company now owns 20,175 shares of the company’s stock worth $4,010,000 after acquiring an additional 12,275 shares during the last quarter. Capital International Sarl grew its stake in shares of BeiGene by 38.3% during the first quarter. Capital International Sarl now owns 172,972 shares of the company’s stock worth $32,623,000 after acquiring an additional 47,918 shares during the last quarter. Capital Group International Inc. CA grew its stake in shares of BeiGene by 14.1% during the first quarter. Capital Group International Inc. CA now owns 1,140,960 shares of the company’s stock worth $215,185,000 after acquiring an additional 141,133 shares during the last quarter. Finally, Capital International Investors boosted its position in BeiGene by 11.2% in the first quarter. Capital International Investors now owns 7,055,295 shares of the company’s stock valued at $1,337,378,000 after buying an additional 711,396 shares during the last quarter.

About BeiGene (Get Rating)

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Read More

Insider Buying and Selling by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.